In8bio annual stock-based compensation
2020
2021
2022
2023
2024
2025
In8bio Stock-Based Compensation Growth & History (INAB)
In8bio's stock-based compensation was $3.2M for fiscal 2025.
View full In8bio company overviewIn8bio annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.2M | −$1.8M | −36.22% |
| 2024 | 2024-12-31 | $5.0M | $630,000 | +14.42% |
| 2023 | 2023-12-31 | $4.4M | $903,000 | +26.05% |
| 2022 | 2022-12-31 | $3.5M | $1.3M | +57.95% |
| 2021 | 2021-12-31 | $2.2M | $1.8M | +514.85% |
| 2020 | 2020-12-31 | $357,000 | — | — |
In8bio quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $352,000 | −$603,000 | −63.14% |
| Q1 2026 | 2026-03-31 | $401,000 | −$430,000 | −51.74% |
| Q4 2025 | 2025-12-31 | $711,000 | −$114,000 | −13.82% |
| Q3 2025 | 2025-09-30 | $692,000 | −$1.1M | −60.77% |
| Q2 2025 | 2025-06-30 | $955,000 | −$216,000 | −18.45% |
| Q1 2025 | 2025-03-31 | $831,000 | −$409,000 | −32.98% |
| Q4 2024 | 2024-12-31 | $825,000 | −$427,000 | −34.11% |
| Q3 2024 | 2024-09-30 | $1.8M | $524,000 | +42.26% |
| Q2 2024 | 2024-06-30 | $1.2M | $152,000 | +14.92% |
| Q1 2024 | 2024-03-31 | $1.2M | $381,000 | +44.35% |
| Q4 2023 | 2023-12-31 | $1.3M | $330,000 | +35.79% |
| Q3 2023 | 2023-09-30 | $1.2M | $343,000 | +38.24% |
| Q2 2023 | 2023-06-30 | $1.0M | $135,000 | +15.27% |
| Q1 2023 | 2023-03-31 | $859,000 | $95,000 | +12.43% |
| Q4 2022 | 2022-12-31 | $922,000 | −$43,000 | −4.46% |
| Q3 2022 | 2022-09-30 | $897,000 | $420,000 | +88.05% |
| Q2 2022 | 2022-06-30 | $884,000 | $492,000 | +125.51% |
| Q1 2022 | 2022-03-31 | $764,000 | $403,000 | +111.63% |
| Q4 2021 | 2021-12-31 | $965,000 | $662,000 | +218.48% |
| Q3 2021 | 2021-09-30 | $477,000 | $461,000 | +2881.25% |
| Q2 2021 | 2021-06-30 | $392,000 | $372,000 | +1860.00% |
| Q1 2021 | 2021-03-31 | $361,000 | $343,000 | +1905.56% |
| Q4 2020 | 2020-12-31 | $303,000 | — | — |
| Q3 2020 | 2020-09-30 | $16,000 | — | — |
| Q2 2020 | 2020-06-30 | $20,000 | — | — |
| Q1 2020 | 2020-03-31 | $18,000 | — | — |
In8bio stock-based compensation trends
Over the last five fiscal years, In8bio's stock-based compensation increased from $357,000 to $3.2M, a change of $2.8M. The latest reported quarter, Q2 2026, shows $352,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review In8bio source filings ↗